Drug targeting TLR5 receptor reduces lung scarring in mice with IPF model

A study in mice shows that a receptor involved in bacterial recognition can influence the development of lung scarring after injury. Researchers deleted the Tlr5 gene and observed greater fibrosis, weight loss, and lower survival compared with mice that retained the receptor.

The receptor, TLR5, normally activates in airway cells after lung damage and limits overgrowth of harmful bacteria. Mice lacking the receptor showed reduced microbial diversity and weaker antimicrobial activity in lung-lining cells.

Genetic and microbial factors Idiopathic pulmonary fibrosis causes progressive lung scarring that impairs breathing. Current treatments slow progression but do not reverse symptoms or extend survival for most patients. The study reports that not all individuals exposed to smoking, infections, or environmental irritants develop the disease, suggesting genetic differences and lung microbiome composition may affect risk.

Next research steps Targeting the TLR5 pathway with drugs could limit bacterial overgrowth after injury and slow fibrosis, according to the researchers. Further studies are needed to test whether similar mechanisms operate in humans.